ACA
Avoro Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $212M | Hold |
12,222,222
| – | – | 3.71% | 7 |
|
|
2025
Q1 | $267M | Hold |
12,222,222
| – | – | 4.17% | 7 |
|
|
2024
Q4 | $390M | Buy |
12,222,222
+1,111,111
| +10% | +$35.5M | 5.52% | 6 |
|
|
2024
Q3 | $320M | Hold |
11,111,111
| – | – | 4.67% | 6 |
|
|
2024
Q2 | $426M | Hold |
11,111,111
| – | – | 5.68% | 7 |
|
|
2024
Q1 | $653M | Hold |
11,111,111
| – | – | 7.62% | 2 |
|
|
2023
Q4 | $665M | Hold |
11,111,111
| – | – | 9.19% | 1 |
|
|
2023
Q3 | $423M | Hold |
11,111,111
| – | – | 6.59% | 5 |
|
|
2023
Q2 | $1.01B | Hold |
11,111,111
| – | – | 13.73% | 1 |
|
|
2023
Q1 | $733M | Buy |
11,111,111
+486,111
| +5% | +$32.1M | 10.87% | 2 |
|
|
2022
Q4 | $549M | Buy |
10,625,000
+500,000
| +5% | +$25.9M | 8.21% | 3 |
|
|
2022
Q3 | $692M | Buy |
10,125,000
+320,000
| +3% | +$21.9M | 12.78% | 1 |
|
|
2022
Q2 | $443M | Buy |
9,805,000
+355,000
| +4% | +$16.1M | 8.76% | 3 |
|
|
2022
Q1 | $480M | Buy |
9,450,000
+894,445
| +10% | +$45.4M | 8.77% | 3 |
|
|
2021
Q4 | $405M | Buy |
8,555,555
+3,555,555
| +71% | +$168M | 6.88% | 4 |
|
|
2021
Q3 | $165M | Buy |
5,000,000
+3,994,770
| +397% | +$132M | 2.59% | 11 |
|
|
2021
Q2 | $63.5M | Buy |
1,005,230
+5,230
| +0.5% | +$331K | 1.11% | 19 |
|
|
2021
Q1 | $42.9M | Buy |
+1,000,000
| New | +$42.9M | 0.74% | 28 |
|
|
2018
Q2 | – | Sell |
-396,635
| Closed | -$7.45M | – | 44 |
|
|
2018
Q1 | $7.45M | Hold |
396,635
| – | – | 0.36% | 35 |
|
|
2017
Q4 | $7.32M | Buy |
+396,635
| New | +$7.32M | 0.47% | 30 |
|